Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded

Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder value FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 13, 2026 / <a rel="nofollow" href="https://pr.report/lia0">Xenetic Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XBIO">XBIO</a>) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.Recent Highlights<ul style="list-style-type:disc;"><li>Generated robust translational data supporting the DNase I platform across multiple oncology settings</li><li>Completed process improvement and analytical development activities supporting future clinical manufacturing readiness</li><li>Established translational and biomarker insights intended to help inform and de-risk future clinical trial design</li><li>Collaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma</li></ul>"We entered 2026 with a clear focus on advancing the translational, manufacturing and clinical foundation of our DNase I platform while maintaining financial discipline," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "During the quarter, we achieved important progress across investigator-initiated studies, translational research and manufacturing readiness activities. We believe the growing body of translational evidence supporting NET-targeting approaches, combined with the expanding understanding of NETs as drivers of tumor progression, immune suppression and therapy resistance, continues to strengthen the potential opportunity for DNase I as a differentiated adjunctive immuno-oncology therapy across multiple cancer settings."Xenetic's proprietary DNase technology is being developed as a potential adjunctive therapeutic approach designed to improve the effectiveness of existing cancer treatments, including immunotherapies, through the targeting of NETs, which are increasingly recognized as key drivers of immune suppression and therapeutic resistance within the tumor microenvironment.Summary of Financial Results for First Quarter 2026Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd.Research and development expenses for the three months ended March 31, 2026 decreased approximately 25% to approximately $0.7 million from approximately $0.9 million for the comparable prior year period, primarily due to lower preclinical and exploratory study costs, partially offset by increased manufacturing development efforts supporting the Company's DNase I program.General and administrative expenses for the three months ended March 31, 2026 decreased by approximately 1.4%, to approximately $0.6 million from approximately $0.7 million in the comparable quarter in 2025. The decrease was primarily due to a decrease in personnel costs and share-based expenses related to our interim Chief Executive Officer substantially offset by an increase in legal expenses related to our strategic review process during the first quarter of 2026 compared to the same period in 2025.Net loss for the quarter ended March 31, 2026 decreased approximately 49% to approximately $0.5 million, compared to approximately $0.9 million for the same period in 2025.The Company ended the first quarter of 2026 with approximately $7.3 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.For more information, please visit the Company's website at <a rel="nofollow" href="https://pr.report/lia1">www.xeneticbio.com</a> and connect on <a rel="nofollow" href="https://pr.report/lia2">X</a>, <a rel="nofollow" href="https://pr.report/lia3">LinkedIn</a>, and <a rel="nofollow" href="https://pr.report/lia4">Facebook</a>.Forward-Looking StatementsThis press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding future clinical development, manufacturing readiness and trial design, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, our belief regarding strengthening the potential opportunity for DNase I as an adjunctive therapy across multiple cancer settings and our focus on advancing DNase into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.Contact:JTC Team, LLC Jenene Thomas (908) 824-0775 <a rel="nofollow" href="mailto:xbio@jtcir.com">xbio@jtcir.com</a>SOURCE: Xenetic Biosciences, Inc. View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-conti-1166337'>press release</a> on ACCESS Newswire 
 <img src="https://app.accessnewswire.com/img.ashx?id=1166337" width="0" height="0"/>

XBIO

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Xenetic Biosciences Reports Positive Financial Results and Progress in Cancer Research

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Xenetic Biosciences announced significant financial improvements and advances in its DNase I platform. The company&#039;s Q1 2026 results show a 36% rise in royalty revenue and decreased net losses, which may enhance investor sentiment and facilitate future initiatives, especially in oncology.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Xenetic reports 36% increase in royalty revenue for Q1 2026.</li><li>Company completed activities for clinical manufacturing readiness.</li><li>Net loss decreased by 49% year-over-year to approximately $0.5 million.</li><li>Strong financial position with approximately $7.3 million in cash.</li><li>Approval for exploratory DNase I study in collaboration with CAR T-cell therapy.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Takeda Pharmaceuticals (TKPHF): Collaboration on royalty agreements strengthens Xenetic&#039;s financial stability.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news falls under &#039;Corporate Developments&#039; as it involves advancements in product readiness and strategic financial disclosure, critical for maintaining investor confidence.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Approval of exploratory studies may attract investor interest and enhance stock value.</li><li>Increased royalty revenue highlights effective partnerships, potentially boosting cash flows.</li><li>Reduction in net losses indicates improved operational efficiency, appealing to cost-conscious investors.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Royalty revenue for Q1 2026 increased to $0.8 million from $0.6 million.</li><li>Net loss decreased from $0.9 million to $0.5 million year-over-year.</li><li>The company ended Q1 2026 with approximately $7.3 million in cash.</li><li>Clinical manufacturing readiness activities have been completed for DNase I.</li><li>Israeli Ministry of Health approved a collaborative study involving DNase I therapy.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider buying XBIO to leverage upcoming clinical developments and improved financials in the next 6-12 months.
 </section>
</section>


Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder value FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 13, 2026 / <a rel="nofollow" href="https://pr.report/lia0">Xenetic Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XBIO">XBIO</a>) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.Recent Highlights<ul style="list-style-type:disc;"><li>Generated robust translational data supporting the DNase I platform across multiple oncology settings</li><li>Completed process improvement and analytical development activities supporting future clinical manufacturing readiness</li><li>Established translational and biomarker insights intended to help inform and de-risk future clinical trial design</li><li>Collaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma</li></ul>"We entered 2026 with a clear focus on advancing the translational, manufacturing and clinical foundation of our DNase I platform while maintaining financial discipline," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "During the quarter, we achieved important progress across investigator-initiated studies, translational research and manufacturing readiness activities. We believe the growing body of translational evidence supporting NET-targeting approaches, combined with the expanding understanding of NETs as drivers of tumor progression, immune suppression and therapy resistance, continues to strengthen the potential opportunity for DNase I as a differentiated adjunctive immuno-oncology therapy across multiple cancer settings."Xenetic's proprietary DNase technology is being developed as a potential adjunctive therapeutic approach designed to improve the effectiveness of existing cancer treatments, including immunotherapies, through the targeting of NETs, which are increasingly recognized as key drivers of immune suppression and therapeutic resistance within the tumor microenvironment.Summary of Financial Results for First Quarter 2026Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd.Research and development expenses for the three months ended March 31, 2026 decreased approximately 25% to approximately $0.7 million from approximately $0.9 million for the comparable prior year period, primarily due to lower preclinical and exploratory study costs, partially offset by increased manufacturing development efforts supporting the Company's DNase I program.General and administrative expenses for the three months ended March 31, 2026 decreased by approximately 1.4%, to approximately $0.6 million from approximately $0.7 million in the comparable quarter in 2025. The decrease was primarily due to a decrease in personnel costs and share-based expenses related to our interim Chief Executive Officer substantially offset by an increase in legal expenses related to our strategic review process during the first quarter of 2026 compared to the same period in 2025.Net loss for the quarter ended March 31, 2026 decreased approximately 49% to approximately $0.5 million, compared to approximately $0.9 million for the same period in 2025.The Company ended the first quarter of 2026 with approximately $7.3 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.For more information, please visit the Company's website at <a rel="nofollow" href="https://pr.report/lia1">www.xeneticbio.com</a> and connect on <a rel="nofollow" href="https://pr.report/lia2">X</a>, <a rel="nofollow" href="https://pr.report/lia3">LinkedIn</a>, and <a rel="nofollow" href="https://pr.report/lia4">Facebook</a>.Forward-Looking StatementsThis press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding future clinical development, manufacturing readiness and trial design, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, our belief regarding strengthening the potential opportunity for DNase I as an adjunctive therapy across multiple cancer settings and our focus on advancing DNase into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.Contact:JTC Team, LLC Jenene Thomas (908) 824-0775 <a rel="nofollow" href="mailto:xbio@jtcir.com">xbio@jtcir.com</a>SOURCE: Xenetic Biosciences, Inc. View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-conti-1166337'>press release</a> on ACCESS Newswire 
 <img src="https://app.accessnewswire.com/img.ashx?id=1166337" width="0" height="0"/>

Xenetic Biosciences announced significant financial improvements and advances in its DNase I platform. The company's Q1 2026 results show a 36% rise in royalty revenue and decreased net losses, which may enhance investor sentiment and facilitate future initiatives, especially in oncology.

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News